Kyntra Bio Inc KYNB
6.94
(0.06)
(0.86%)
as of 25 Sep
- Market cap
- $28.3M
- P/E
- 0.2×
Follow KYNB
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (157.83%) | (144.04%) | (165.18%) | (189.86%) |
+8 more TTM periods Free account |
|
| 131.26% | 119.06% | 109.81% | 107.44% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
301.38% | 223.39% | 262.71% | 221.30% | |
Average Days of Receivables |
27.43 | 247.29 | 12.24 | 5.32 | |
Free Cash Flow per Share |
(9.40) | (5.28) | (1.19) | (4.18) | |
Free Cash Flow |
(38.05) | (21.38) | (4.81) | (16.88) | |
Capital Expenditures |
— | — | (0.04) | 0.03 | |
Piotroski F-Score |
5.00 | 5.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(61.68%) | (37.86%) | (6.63%) | (14.84%) | |
Accounts Receivable Turnover |
19.12 | 2.87 | 18.48 | 0.57 | |
Accounts Payable Turnover |
0.48 | 0.71 | 0.13 | (0.78) | |
Inventory Turnover |
1.19 | 1.35 | 0.16 | (0.40) | |
Average Days of Payables |
633.50 | 421.61 | 2,458.50 | (333.86) | |
Days of Inventory on Hand |
285.45 | 280.08 | 2,457.19 | (253.30) | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
495.21% | 294.50% | 365.17% | 278.56% | |
Selling, General and Administrative Expense of Revenue |
599.39% | 342.32% | 430.26% | 347.10% | |
Share Based Compensation of Revenue |
86.33% | 65.53% | 102.11% | 67.06% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.21) | (0.13) | (0.03) | (0.08) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | 0.02 | |
Revenue per Share |
1.14 | 1.84 | 1.59 | 2.05 | |
Operating CF per Share |
(9.40) | (5.28) | (1.18) | (4.18) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.01 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Net Profit Margin |
3,967.77% | 2,199.42% | 2,848.63% | 2,598.55% |
Columns are period end dates